TGTX Tg Therapeutics Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: TGTX

Price (delayed)

$16.45

Market cap

$2.49B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.2

Enterprise value

$2.45B

TG Therapeutics is a fully-integrated, commercial stage biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. In addition to an active ...

Highlights
Tg Therapeutics's EPS has surged by 89% YoY and by 84% QoQ
The company's net income has surged by 89% YoY and by 85% QoQ
The quick ratio has soared by 108% QoQ but it has decreased by 3.7% YoY
TGTX's debt is up by 34% YoY
Sector: Healthcare
Industry: Biotechnology
Website: http://www.tgtherapeutics.com
Peers: ALIM

Key stats

What are the main financial stats of TGTX
Market
Shares outstanding
151.41M
Market cap
$2.49B
Enterprise value
$2.45B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
15.07
Price to sales (P/S)
12.38
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
12.89
Earnings
Revenue
$189.77M
EBIT
-$12.86M
EBITDA
-$12.61M
Free cash flow
-$42.08M
Per share
EPS
-$0.2
Free cash flow per share
-$0.29
Book value per share
$1.09
Revenue per share
$1.33
TBVPS
$2.31
Balance sheet
Total assets
$331.07M
Total liabilities
$166.3M
Debt
$108.43M
Equity
$164.77M
Working capital
$261.44M
Liquidity
Debt to equity
0.66
Current ratio
5.53
Quick ratio
4.68
Net debt/EBITDA
3.47
Margins
EBITDA margin
-6.6%
Gross margin
96.7%
Net margin
-13.7%
Operating margin
-10%
Efficiency
Return on assets
-11%
Return on equity
-35.6%
Return on invested capital
-7.6%
Return on capital employed
-4.7%
Return on sales
-6.8%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

TGTX stock price

How has the Tg Therapeutics stock price performed over time
Intraday
14.87%
1 week
31.71%
1 month
60.49%
1 year
96.54%
YTD
39.05%
QTD
96.77%

Financial performance

How have Tg Therapeutics's revenue and profit performed over time
Revenue
$189.77M
Gross profit
$183.49M
Operating income
-$18.94M
Net income
-$25.91M
Gross margin
96.7%
Net margin
-13.7%
TGTX's net margin has soared by 100% YoY and by 98% QoQ
Tg Therapeutics's operating margin has surged by 100% YoY and by 99% QoQ
The operating income has soared by 92% YoY and by 89% from the previous quarter
The company's net income has surged by 89% YoY and by 85% QoQ

Growth

What is Tg Therapeutics's growth rate over time

Valuation

What is Tg Therapeutics stock price valuation
P/E
N/A
P/B
15.07
P/S
12.38
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
12.89
Tg Therapeutics's EPS has surged by 89% YoY and by 84% QoQ
The P/B is 75% below the last 4 quarters average of 52.2 and 50% below the 5-year quarterly average of 26.0
The equity has surged by 64% year-on-year
The P/S is 100% below the 5-year quarterly average of 5729.9 and 96% below the last 4 quarters average of 243.5

Efficiency

How efficient is Tg Therapeutics business performance
Tg Therapeutics's return on sales has surged by 100% YoY and by 99% QoQ
TGTX's ROIC has soared by 96% YoY and by 93% QoQ
The company's return on equity has surged by 89% QoQ and by 76% YoY
The ROA has soared by 87% from the previous quarter and by 87% YoY

Dividends

What is TGTX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for TGTX.

Financial health

How did Tg Therapeutics financials performed over time
The total assets is 99% higher than the total liabilities
The quick ratio has soared by 108% QoQ but it has decreased by 3.7% YoY
TGTX's current ratio has soared by 93% since the previous quarter and by 10% year-on-year
TGTX's debt is 34% lower than its equity
The debt to equity has plunged by 75% from the previous quarter and by 18% YoY
The equity has surged by 64% year-on-year

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.